HD 1991: all centres/groups, trials/strata and treatments

Key: Green - ineligible for overview, nonstandard randomisation or otherwise excluded; Blue - data not (yet) received

11 GATLA, Buenos Aires, Argentina {Pavlovsky: JUL-1991}

1101 72H Chemotherapy Trial: Stage I, II, III, IV; Entry 1972 to 1977; 303 patients were entered (not received)

1 Cyclophosphamide + Vinblastine + Procarbazine + Prednisone
2 Cyclophosphamide + Vinblastine + Procarbazine + Prednisone + Lomustine

1102 77F1 LYH 7801, Induction: Stage I, II, III, IV; Entry 1977 to 1986; 439 patients were entered (not received)

1 Cyclophosphamide + Vinblastine + Procarbazine + Prednisone
2 Cyclophosphamide + Vinblastine + Procarbazine + Prednisone + Radiotherapy [30Gy, involved field]

1103 77F2 LYH 7801, Maintenance: Stage I, II, III, IV; Entry 1977 to 1986; ? patients were entered (not received)

1 Control
2 Levamisole

1104 86E1 GATLA 11HD86, Good Prognosis: Stage I, II, IIIa; Entry 1986 ff; 47 patients were entered by SEP-1991 (not received)

1 (Cyclophosphamide + Vinblastine + Procarbazine + Prednisone) x 6
2 (Cyclophosphamide + Vinblastine + Procarbazine + Prednisone) x 3

1105 86E2 GATLA 11HD86, Intermediate Prognosis: Stage I, II, IIIa; Entry 1986 ff; 126 patients were entered by SEP-1991 (not received)

1 (Cyclophosphamide + Vinblastine + Procarbazine + Prednisone) x 3 then Radiotherapy then (Cyclophosphamide + Vinblastine + Procarbazine + Prednisone) x 3
2 (Doxorubicin + Vincristine + Prednisone + Etoposide) then Radiotherapy then (Doxorubicin + Vincristine + Prednisone + Etoposide)

12 National Cancer Institute of Canada, Canada {Pater: JUL-1991}

1201 72F1 NCIC-HD1, First Randomisation: Stage IIIb, IV; Entry 1972 to 1976; 167 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 3 + Radiotherapy [2-3000rad to abdomen and upper mantle]
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6

1202 72F2 NCIC-HD1, Second Randomisation: Stage IIIb, IV; Patients from arm 2 of 1201; Entry 1972 to 1976; 100 patients were entered {THIS ENTRY IS WRONG!} (not received)

1 Control
2 Radiotherapy
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 4

1203 75C1 NCIC-HD2: Stage IIb, III; Age < 21; Entry 1976 to 1979; ? patients were entered (synthetic data only, groups 1 and 2; no event; not received)

1 Radiotherapy ['more']
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy ['less']
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

1204 75C2 NCIC-HD3: Stage IIIb, IV; Age < 70; Entry 1977 to 1980; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy [low dose]
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy [high dose]
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy [low dose] then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
4 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy [high dose] then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

1205 84A NCIC-HD4: Stage III, IV; Entry 1984 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine)

13 German Hodgkin's Disease Study Group, Germany {Diehl, Löffler: JAN-1992}

1301 83A1 HD-1: Stage I, II, IIIA; Age 15-60; Entry 1984 to 1988; 180 patients were entered (not received)

1 (Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then Radiotherapy [extended field, 40Gy]
2 (Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then Radiotherapy [extended field 20Gy, bulk 20Gy]

1302 83A2 HD-2: Stage IIIA,N; Entry APR-1983 to OCT-1987; 19 patients were entered

1 Radiotherapy [total nodal, 40Gy]
2 (Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then Radiotherapy [involved field, 20Gy]

1303 83A3 HD-3: Stage IIIB, IV; Entry 1984 to 1988; 110 patients were entered (not received)

1 (Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then Radiotherapy [involved field]
2 (Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then (Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

1304 88A HD-4: Stage I, II; Entry 1988 ff; ? patients were entered (not received)

1 Radiotherapy [extended field, 40Gy]
2 Radiotherapy [extended field, 30Gy] + Radiotherapy [involved field, 10Gy]

1305 88C1 HD-5: Stage I, II Poor Prognosis, IIIA; Entry 1988 ff; 500 patients were entered by SEP-1991 (not received)

1 ((Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)) x 2 + Radiotherapy [30Gy extended field, 10Gy bulk]
2 ((Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine + IMEP)) x 2 + Radiotherapy [30Gy extended field, 10Gy bulk]

1306 88C2 HD-6: Stage IIIb, IV; Entry 1988 ff; 360 patients were entered by SEP-1991 (not received)

1 ((Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)) x 4 + Radiotherapy [30Gy]
2 ((Cyclophosphamide + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine + IMEP)) x 4 + Radiotherapy [30Gy]

1307 Resistant Disease: Entry ????; ? patients were entered (not received)

1 DexaBEAM + GM-Colony Stimulating Factor
2 DexaBEAM

14 British National Lymphoma Investigation, U.K. {Vaughan-Hudson: JUN-1992}

1401 70C1 HD01-02 (Laparotomy Series): Stage IA, IIA; Entry MAY-1970 to APR-1979; 326 patients were entered

1 Radiotherapy (involved field)
2 Radiotherapy (extended field)

1402 70C2 HD03-04 (Non-Laparotomy Series): Stage IA, IIA; Entry MAR-1970 to APR-1979; 209 patients were entered

1 Radiotherapy (involved field)
2 Radiotherapy (extended field)

1403 70G Radiotherapy/Chemotherapy Trial: Stage III; Entry 1970 ff; ? patients were entered (not received)

1 Radiotherapy (total nodal)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

1404 __A1 Chemotherapy Trial: Stage IIIB, IV; Entry ????; ? patients were entered (not received)

1 (Mechlorethamine + Vinblastine + Procarbazine)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

1405 __A2 Chemotherapy Trial: Stage IIIB, IV; Entry ????; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin

1406 __A3 Chemotherapy Trial: Stage IIIB, IV; Entry ????; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Lomustine + Vinblastine + Bleomycin)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin + (Lomustine + Vinblastine + Bleomycin)

1407 75A HD23-24: Stage IIIA; Entry NOV-1975 to SEP-1980; 100 patients were entered

1 Radiotherapy (total nodal) + (Chlorambucil + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (total nodal)

1408 79A Chemotherapy Trial: Stage III, IV; Entry 1979 to 1983; 299 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Chlorambucil + Vincristine + Procarbazine + Prednisone)

1409 83B Chemotherapy Trial: Stage Ib, IIb, III, IV; Entry 1983 to 1990; 594 patients were entered (not received)

1 Chlorambucil + Vincristine + Procarbazine + Prednisolone
2 Chlorambucil + Vincristine + Procarbazine + Prednisolone + Etoposide + Vinblastine + Doxorubicin + Prednisolone

1410 90C1 LOPP/EVA(P) Trial: Stage Ib, IIb, III, IV (poor prognosis); Entry JAN-1990 to SEP-1991; 180 patients were entered (not received)

1 ((Chlorambucil + Vincristine + Procarbazine + Prednisolone) / (4-Epi-Doxorubicin + Vincristine + Doxorubicin + Prednisolone)) x 6
2 ((Chlorambucil + Vincristine + Procarbazine + Prednisolone) / (4-Epi-Doxorubicin + Vincristine + Doxorubicin) hybrid) x 6

1411 90C2 Radiotherapy Trial: Stage Ib, IIb, III, IV (CR); Entry JAN-1990 to SEP-1991; ? patients were entered (not received)

1 Control
2 Radiotherapy [35Gy, nodal > 2cm]

1412 70C3 HD10 (Laparotomy Series): Stage IB, IIB; Entry AUG-1970 to APR-1978; 42 patients were entered

1 Radiotherapy (mantle)
2 Radiotherapy (total nodal)

1413 70C4 HD11 (Non-Laparotomy Series): Stage IB, IIB; Entry JUN-1970 to AUG-1975; 12 patients were entered

1 Radiotherapy (mantle)
2 Radiotherapy (total nodal)

15 Manchester Lymphoma Group, U.K. {Crowther: SEP-1991}

1501 74B Christie HD1 Trial: Stage I, II; Age 16-65; Entry OCT-1974 to AUG-1981; 121 patients were entered (6 patients missing)

1 Radiotherapy (mantle)
2 Radiotherapy (mantle) + (Mechlorethamine + Vinblastine + Procarbazine + Prednisone)

1502 74K Christie HD2 Trial: Stage IIIA; Entry 1975 to 1982; 56 patients were entered (not received)

1 (Mechlorethamine + Vinblastine + Procarbazine + Prednisone) + Radiotherapy (to previous disease sites)
2 (Mechlorethamine + Vinblastine + Procarbazine + Prednisone)

1503 85B Chemotherapy Trial: Stage I-IV; Entry 1985 ff; 350 patients were entered by 1991 (not received)

1 Mustine + Vinblastine + Procarbazine + Prednisone
2 Vinblastine + Doxorubicin + Etoposide + Vincristine + Chlorambucil + Procarbazine + Prednisone

16 Cancer and Leukemia Group B, U.S.A. {Anderson: JUL-1991}

1601 59A1 Chemotherapy Trial: Patients with other neoplastic diseases were also entered; Entry 1959 ff; ? patients were entered (not received)

1 Cyclophosphamide
2 Uracil Mustard
3 Mechlorethamine

1602 59A2 Chemotherapy Trial, Induction: Patients with other lymphomas were also entered; Entry 1962 ff; ? patients were entered (not received)

1 Cyclophosphamide
2 Vinblastine

1603 59A3 Chemotherapy Trial, Maintenance: Stage III, IV; Patients with other lymphomas were also entered; Entry 1962 ff; ? patients were entered (not received)

1 Cyclophosphamide
2 Placebo

1604 59A4 Chemotherapy Trial: Stage III, IV; Patients with other lymphomas were also entered; Entry 1965 to 1967; ? patients were entered (not received)

1 Carmustine [250mg/m² iv] x 1
2 Carmustine [168mg/m² iv] x 1
3 Carmustine [90mg/m² iv once weekly] x 6wk
4 Carmustine [60mg/m² iv once weekly] x 6wk

1605 65C CLB-6609, Part 1: Stage III; Entry 1965 to 1966; ? patients were entered (not received)

1 Vinblastine + Mechlorethamine (concurrent)
2 Vinblastine + Mechlorethamine (sequential)

1606 66A CLB-6609, Part 2: Stage III; Entry 1966 to 1971; ? patients were entered (synthetic data, groups 2 and 3 only with no event; not received)

1 Vinblastine + Mechlorethamine
2 Vinblastine + Mechlorethamine + Radiotherapy (involved field)
3 Vinblastine + Mechlorethamine then Radiotherapy (total nodal)
4 Radiotherapy (total nodal) then Vinblastine + Mechlorethamine
5 Radiotherapy (total nodal)

1607 67D CLB-6712: Stage III, IV; Entry 1967 to 1969; 260 patients were entered (not received)

1 Vincristine + Procarbazine + Vinblastine + Chlorambucil + Prednisone (concurrent)
2 Vincristine + Procarbazine + Vinblastine + Chlorambucil + Prednisone (sequential)
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

1608 69A1 CLB-6951, Induction: Stage IIIB, IV; Entry 1969 to 1971; 460 patients were entered (not received)

1 Vincristine + Prednisone + Procarbazine + Carmustine
2 Mechlorethamine + Vincristine + Procarbazine + Prednisone
3 Vincristine + Prednisone + Carmustine
4 Vincristine + Procarbazine + Prednisone

1609 69A2 CLB-6951, Maintenance: Stage IIIB, IV; Entry 1969 to 1971; ? patients were entered (not received)

1 Vinblastine
2 Chlorambucil
3 Chlorambucil + Vincristine + Prednisone

1610 69A3 CLB-6951, Additional Therapy: Stage IIIB, IV; Entry 1969 to 1971; ? patients were entered (not received)

1 3 courses of the patient's induction therapy
2 12 courses of the patient's maintenance therapy

1611 69A4 CLB-6951A, Induction: Stage IIIB, IV; Entry 1971 to 1972; 122 patients were entered (not received)

1 Vincristine + Prednisone + Procarbazine + Carmustine
2 Mechlorethamine + Vincristine + Procarbazine + Prednisone
3 (Carmustine + Vincristine + Procarbazine + Prednisone) [half dose of V]
4 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) [half dose of V]

1612 69A5 CLB-6951A, Maintenance: Stage IIIB, IV; Entry 1971 to 1972; ? patients were entered (not received)

1 Vinblastine
2 Chlorambucil
3 Chlorambucil + Vincristine + Prednisone

1613 69A6 CLB-6951A, Additional Therapy: Stage IIIB, IV; Entry 1971 to 1972; ? patients were entered (not received)

1 3 courses of the patient's induction therapy
2 12 courses of the patient's maintenance therapy

1614 72C1 CLB-7251, Induction: Stage III, IV; Entry 1972 to 1975; 566 patients were entered (not received)

1 Mechlorethamine + Vincristine + Procarbazine + Prednisone
2 Mechlorethamine + Vinblastine + Procarbazine + Prednisone
3 Lomustine + Vincristine + Procarbazine + Prednisone
4 Lomustine + Vinblastine + Procarbazine + Prednisone

1615 72C2 CLB-7251, Maintenance: Stage III, IV; Entry 1972 to 1975; ? patients were entered (not received)

1 Vinblastine
2 Vinblastine + repeat course of patient's induction therapy
3 Vinblastine + MER
4 Vinblastine + MER + repeat course of patient's induction therapy

1616 70D CLB-????: Stage III, IV; Entry 1970 ff; ? patients were entered (not received)

1 Carmustine
2 Lomustine

1617 72D CLB-7252: Stage III, IV; Refractory disease; Patients with other lymphomas were also entered; Entry 1972 to 1973; ? patients were entered (not received)

1 Lomustine
2 MeCCNU

1618 74C1 CLB-7451, Part 1: Stage III; Entry 1974 to 1978; ? patients were entered (synthetic data, groups 1 and 3 only, no event; not received)

1 Radiotherapy (total nodal)
2 (Carmustine + Vincristine + Procarbazine + Prednisone) + Chlorambucil
3 Radiotherapy (total nodal) then (Carmustine + Vincristine + Procarbazine + Prednisone) x 6
4 (Carmustine + Vincristine + Procarbazine + Prednisone) x 6 then Radiotherapy (total nodal)

1619 74C2 CLB-7451, Part 2: Stage III; Entry 1978 to 1979; ? patients were entered (not received)

1 Radiotherapy (total nodal)
2 (Carmustine + Vincristine + Procarbazine + Prednisone)
3 Radiotherapy (total nodal) then (Carmustine + Vincristine + Procarbazine + Prednisone) x 6
4 (Carmustine + Vincristine + Procarbazine + Prednisone) x 6 then Radiotherapy (total nodal)

1620 74C3 CLB-7451, Part 3: Stage IIIA; Entry 1979 to 1981; ? patients were entered (not received)

1 Radiotherapy (total nodal)
2 Carmustine + Vincristine + Procarbazine + Prednisone
3 Radiotherapy (total nodal) then (Carmustine + Vincristine + Procarbazine + Prednisone) x 6

1621 75D CLB-7551: Stage IIIB after 1979, IV; Entry 1975 to 1981; 305 patients were entered (not received)

1 (Lomustine + Vinblastine + Procarbazine + Prednisone) x 6
2 (Lomustine + Vinblastine + Procarbazine + Prednisone) x 12
3 (Lomustine + Vinblastine + Procarbazine + Prednisone) x 6 then Radiotherapy
4 (Lomustine + Vinblastine + Procarbazine + Prednisone) x 3 then Radiotherapy then (Lomustine + Vinblastine + Procarbazine + Prednisone) x 3

1622 75K1 CLB-7552, Part 1, Induction: Stage IIIB, IV; Entry 1975 to 1979; ? patients were entered (not received)

1 Lomustine + Vinblastine + Procarbazine + Prednisone
2 (Lomustine + Vinblastine + Procarbazine + Prednisone) + MER
3 Bleomycin + Doxorubicin + Vincristine + Streptozotocin
4 Bleomycin + Doxorubicin + Vincristine + Streptozotocin + MER
5 (Lomustine + Vinblastine + Procarbazine + Prednisone) + (Bleomycin + Doxorubicin + Vincristine + Streptozotocin)
6 (Lomustine + Vinblastine + Procarbazine + Prednisone) + (Doxorubicin + Vincristine + Streptozotocin) + MER

1623 75K2 CLB-7552, Part 2, Induction: Stage IIIB, IV; Entry 1979 to 1981; ? patients were entered (not received)

1 Lomustine + Vinblastine + Procarbazine + Prednisone
2 Bleomycin + Doxorubicin + Vincristine + Streptozotocin
3 (Lomustine + Vinblastine + Procarbazine + Prednisone) + (Bleomycin + Doxorubicin + Vincristine + Streptozotocin)

1624 75K3 CLB-7552, Maintenance: Stage IIIB, IV; Entry 1975 to 1979; ? patients were entered (not received)

1 Chlorambucil
2 Chlorambucil + MER

1625 77D CLB-7751: Stage I, II; Entry 1977 to 1983; ? patients were entered (synthetic data, groups 1 and 2 only, no event; not received)

1 Radiotherapy (involved field) + (Lomustine + Vinblastine + Procarbazine + Prednisone)
2 Radiotherapy (extended field) + (Lomustine + Vinblastine + Procarbazine + Prednisone)
3 (Lomustine + Vinblastine + Procarbazine + Prednisone)

1626 82A CLB-8251: Stage III, IV; Age > 16; Entry 1982 to 1987; 400 patients were entered (not received)

1 Mechlorethamine + Vincristine + Procarbazine + Prednisone
2 Doxorubicin + Bleomycin + Vinblastine + Dacarbazine
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

1627 90B INT-0111: Advanced Disease; Entry 1990 ff; ?? patients were entered (not received)

1 Mechlorethamine + Vincristine + Procarbazine + Prednisone
2 Hybrid Regimen

1628 ABVD vs. Hybrid Regimen: Entry ??; ?? patients were entered (not received)

1 Doxorubicin + Bleomycin + Vinblastine + Dacarbazine
2 Hybrid Regimen

1629 91B EVA Trial: Stage I, II; Entry 1991 ff; ?? patients were entered (not received)

1 Radiotherapy
2 Radiotherapy + Etoposide + Vinblastine + Doxorubicin

17 Eastern Coöperative Oncology Group, U.S.A. {Cassileth: JUL-1992}

1701 __B1 Chemotherapy Trial: Stage III, IV; Patients with melanoma were also entered; Entry ????; 59 patients with Hodgkin's disease were entered (not received)

1 TSPA [high dose]
2 TSPA [low dose]
3 Mechlorethamine [high dose]
4 Mechlorethamine [low dose]

1702 __B2 Chemotherapy Trial: Patients with other lymphomas were also entered; Entry ????; ? patients were entered (not received)

1 Dichloromethotrexate
2 Mechlorethamine

1703 72E1 EST-2472, Induction: Stage IIIB, IV; Entry 1972 to 1976; 370 patients were entered (not received)

1 Mechlorethamine + Vincristine + Procarbazine + Prednisone
2 Carmustine + Cyclophosphamide + Vinblastine + Pvb + Prednisone

1704 72E2 EST-2472, Maintenance: Stage IIIB, IV; Entry 1972 to 1976; 148 patients were entered (not received)

1 Carmustine + Cyclophosphamide + Vinblastine + Pvb + Prednisone
2 Control
3 BCG

1705 74L EST-1474: Stage IIIB, IV; Entry 1974 to 1977; ? patients were entered (not received)

1 Bleomycin
2 Teniposide

1706 76C1 EST-1476, Induction: Stage IIIB, IV; Entry 1976 to 1977; ? patients were entered (not received)

1 (Bleomycin + Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Radiotherapy
2 (Bleomycin + Mechlorethamine + Vincristine + Procarbazine + Prednisone) then (Doxorubicin + Vinblastine + Dacarbazine + Bleomycin)

1707 76C2 EST-1476, Maintenance: Stage IIIB, IV; Entry 1976 to 1977; ? patients were entered (not received)

1 Control
2 BCG

1708 76C3 EST-1476R: Stage IIIB, IV; Entry 1977 to 1981; ? patients were entered (not received)

1 (Bleomycin + Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Radiotherapy
2 (Bleomycin + Mechlorethamine + Vincristine + Procarbazine + Prednisone) then (Doxorubicin + Vinblastine + Dacarbazine + Bleomycin)

1709 76B1 EST-2475, Favourable Histopathology: Stage I, II; Age 15-65; Entry OCT-1976 to SEP-1977; 17 patients were entered (no recurrence information; but not marked thus as only 1 death)

1 Radiotherapy (segmental field) + (Nitrogen Mustard/Cyclophosphamide + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (extended field + para-aortic + portahepatic + splenic pedicle) + (Nitrogen Mustard/Cyclophosphamide + Vincristine + Procarbazine + Prednisone) on relapse

1710 76B2 EST-2475, Unfavourable Histopathology: Stage I, II; Age 15-65; Entry JUN-1976 to AUG-1977; 17 patients were entered (no recurrence information; but not marked thus as no deaths either)

1 Radiotherapy (total nodal) + (Nitrogen Mustard/Cyclophosphamide + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (extended field + para-aortic + portahepatic + splenic pedicle) + (Nitrogen Mustard/Cyclophosphamide + Vincristine + Procarbazine + Prednisone) on relapse

1711 77J EST-1477: Stage III, IV; Entry 1977 to 1978; ? patients were entered (not received)

1 Razoxane (loading course)
2 Razoxane (weekly course)

1712 79B EST-1478: Stage III, IV; Age 15-76; Entry 1979 to 1980; ? patients were entered (not received)

1 Teniposide + Cis-Platinum + Prednisone
2 Teniposide + Hexamethylmelamine + Vitamin-B6 + Prednisone

1713 81A EST-1481: Stage III, IV; Age > 16; Entry 1981 to 1987; 305 patients were entered (not received)

1 Carmustine + Cyclophosphamide + Vinblastine + Procarbazine + Prednisone
2 Carmustine + Cyclophosphamide + Vinblastine + Procarbazine + Prednisone + Radiotherapy
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

1714 87A EST-4486 / INT-0074: Stage III, IV; Age 16-65; Entry 1987 to 1989; 737 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6-8 then (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 3
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone + Doxorubicin + Bleomycin + Vinblastine) x 8

18 Roswell Park Memorial Institute, U.S.A. {Henderson: JUL-1991}

1801 63A1 Chemotherapy Trial: Patients with other lymphomas were also entered; Entry 1963 to 1964; 37 patients with Hodgkin's disease were entered (not received)

1 Vinblastine
2 Cyclophosphamide

1802 63A2 Chemotherapy Trial: Stage III, IV; Entry 1965 to 1967; 34 patients were entered (not received)

1 Mechlorethamine
2 Vinblastine

1803 71G Staging Trial: Stage I, II, III, IV; Patients with non-Hodgkins lymphoma were also entered; Entry 1971 to 1974; 89 patients with Hodgkin's disease were entered (not received)

1 Open staging (laparatomy)
2 Closed staging (lymphangiogram, biopsies etc)

1804 71C Radiotherapy Trial: Stage IB, IIB, III; Entry 1971 ff; NONEXISTENT TRIAL (not received)

1 Radiotherapy (inverted Y)
2 Radiotherapy (total abdomen)

1805 71B Chemotherapy Trial: Stage I, II, III; Entry 1971 to 1979; 164 patients were entered (synthetic data only, no event; not received)

1 Radiotherapy
2 Radiotherapy + Vincristine + Vinblastine + Chlorambucil + Procarbazine + Prednisone

19 St Jude's Children's Research Hospital, Memphis, U.S.A. {Thompson: JUL-1991}

1901 72B Chemotherapy Trial: Stage II, IIIA; Age < 21; Entry 1972 to 1975; 32 patients were entered (synthetic data only; no recurrence information)

1 Radiotherapy (mantle + inverted Y)
2 Radiotherapy (mantle + inverted Y) + Vincristine + Cyclophosphamide + Procarbazine

1902 72G Radiotherapy Trial: Stage IIB, IIIB, IV; Age < 21; Entry 1972 to 1975; ? patients were entered (not received)

1 Vincristine + Cyclophosphamide + Procarbazine
2 Vincristine + Cyclophosphamide + Procarbazine + Radiotherapy (mantle + abdomen)

20 Yale University School of Medicine, U.S.A. {Cooper: JUL-1991}

2001 78C Chemotherapy Trial: Stage IIIB, IV; Entry 1978 ff; ? patients were entered (not received)

1 Radiotherapy + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy + (Mechlorethamine + Vincristine + Vinblastine + Procarbazine + Prednisone)

2002 79C Refractory Disease Trial: Entry 1979 to 1980; ? patients were entered (not received)

1 Teniposide
2 Teniposide + Cytosine Arabinoside

2003 83C YALE-HIC-1636: Stage III, IV; Entry 1983 to 1985; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy
2 (Mechlorethamine + Vincristine + Vinblastine + Procarbazine + Prednisone) + Radiotherapy

2004 86B YALE-HIC-3281: Stage III, IV; Entry 1986 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) + Radiotherapy

21 Children's Cancer Study Group, U.S.A. {Hammond: JUL-1991}

2101 75B2 CCG-541 / CALGB-7691: Stage I, II; Age < 18; Entry 1977 to 1981; 114 patients were entered (synthetic data only; no recurrence or stage information)

1 Radiotherapy (involved field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6
2 Radiotherapy (extended field)

2102 86C CCG-521: Stage III, IV; Age < 21; Entry 1986 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)
2 (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) + Radiotherapy (involved field)

22 Pediatric Oncology Group, U.S.A. {Sullivan: JUL-1991}

2201 75B1 POG-7560 / SWOG-7560/7660: Stage I, II; Age < 18; Entry 1975 to 1977; 80 patients were entered (synthetic data only; no recurrence or stage information)

1 Radiotherapy (involved field)
2 Radiotherapy (involved field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2202 76D POG-7612: Stage III; Age < 18; Entry JUL-1976 to OCT-1982; 84 patients were entered (not received)

1 Mechlorethamine + Vincristine + Bleomycin + Procarbazine + Prednisone + Radiotherapy [35Gy, involved field]
2 Doxorubicin + Cyclophosphamide + Vincristine + Procarbazine + Prednisone + Radiotherapy [35Gy, involved field]

2203 86D POG-8625 / POG-8626: Stage IA, IIA, IIIA; Age < 21; Entry 1986 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) then Radiotherapy

2204 87B POG-8725: Stage IIB, III, IV; Age < 21; Entry 1987 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) + Radiotherapy

2205 75B3 POG-7560 / SWOG-7560/7660: Stage I, II; Age < 18; Entry 1977 to 1981; 80 patients were entered (not received; PART OF 2201)

1 Radiotherapy (involved field)
2 Radiotherapy (involved field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6

23 Western Cancer Study Group, U.S.A. {Chlebowski: JUL-1991}

2301 Chemotherapy Trial: Stage III; Entry ????; 50 patients were entered (not received)

1 Mechlorethamine + Chlorambucil
2 Mechlorethamine

2302 71D WCG-114: Resistant Disease; Entry 1971 to 1973; ? patients were entered (not received)

1 Bleomycin (iv)
2 Bleomycin (im)

2303 73A WCG-130: Stage III, IV; Entry 1973 to 1975; ? patients were entered (not received)

1 Mechlorethamine + Vincristine + Procarbazine + Prednisone
2 Lomustine + Vinblastine + Prednisone

2304 74E1 WCG-131, I-B Responders: Disease in Remission; Entry 1974 to 1978; ? patients were entered (not received)

1 Vinblastine
2 Radiotherapy (involved field)

2305 74E2 WCG-131, I-C Responders: Disease in Remission; Entry 1974 to 1978; ? patients were entered (not received)

1 Control
2 Radiotherapy (involved field)

2306 74D WCG-135: Stage II, III; Age < 61; Entry 1974 to 1978; 40 patients were entered (synthetic data, no event; not received)

1 Radiotherapy (total nodal) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (total nodal)

24 Southeastern Cancer Study Group, U.S.A. {Petruska: JUL-1991}

2401 Chemotherapy Trial: Patients with other lymphomas weere also entered; Entry ????; ? patients were entered (not received)

1 Mannitol Mustard
2 Mechlorethamine
3 Cyclophosphamide

2402 67E Chemotherapy Trial: Stage III, IV; Entry 1967 to 1970; 179 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6
2 Mechlorethamine

2403 71E Chemotherapy Trial: Stage IIIB, IV; Entry 1971 to 1975; 327 patients were entered (not received)

1 (Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine) then (Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine)
2 (Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine) then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
3 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine

2404 75E SEG-75HD301: Stage IIIB, IV; Entry 1975 to 1981; ? patients were entered (not received)

1 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine + Doxorubicin + Dacarbazine + Bleomycin
2 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine + Bleomycin

2405 75F SEG-340: Stage III, IV; Entry 1975 to 1977; ? patients were entered (not received)

1 (Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine) then (Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine)
2 (Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine) then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2406 77E SEG-77HD320: Stage I, II, IIIA; Entry 1977 to 1981; ? patients were entered (not received)

1 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine
2 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine + Radiotherapy

2407 82B SEG-HD-81328: Stage IIB, III, IV; Entry 1982 to 1987; ? patients were entered (not received)

1 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine
2 Carmustine + Vinblastine + Cyclophosphamide + Prednisone + Procarbazine + Radiotherapy (tumour)

25 Cape Town University Leukaemia Centre, South Africa {Jacobs: JUL-1991}

2501 82C CT-HD-1: Stage III, IV; Entry 1982 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vinblastine + Vincristine + Procarbazine + Prednisone) x 3
2 (Mechlorethamine + Vinblastine + Vincristine + Procarbazine + Prednisone) x 6
3 (Mechlorethamine + Vinblastine + Vincristine + Procarbazine + Prednisone) x 3 + Radiotherapy
4 (Mechlorethamine + Vinblastine + Vincristine + Procarbazine + Prednisone) x 6 + Radiotherapy

26 Stanford University, U.S.A. {Hoppe: MAY-1993}

2601 62A1 L-1: Stage I, II; Entry JUL-1962 to JUN-1968; 96 patients were entered

1 Radiotherapy [involved field, 4000rad]
2 Radiotherapy [extended field, 4000rad + 3500-4000rad]

2602 62A2 L-2: Stage III; Entry JUL-1962 to APR-1965; 22 patients were entered

1 Radiotherapy [involved field, 1650rad]
2 Radiotherapy [involved field, 4400rad + uninvolved sites]

2603 67A H-1: Stage IA, IIA; Entry JUN-1967 to AUG-1970; 63 patients were entered

1 Radiotherapy [involved field, 4400rad in 4wk]
2 Radiotherapy [total nodal, 4400rad in 4wk]

2604 67F1 H-2: Stage IB, IIB; Entry AUG-1968 to OCT-1979; 54 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy (total nodal) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2605 67F2 H-3: Stage III spleen not involved; Entry JAN-1969 to NOV-1973; 9 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy (total nodal) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2606 67F3 H-4: Stage IB, IIB, III; Entry MAR-1967 to AUG-1973; 22 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy (total nodal) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2607 67F4 H-5: Stage II, III with spleen involved; Entry AUG-1968 to MAR-1974; 92 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy (total nodal) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2608 68C H-6 / H-7 / H-8 / K-7: Stage IV; Entry 1968 to 1974; ? patients were entered (not received)

1 Mechlorethamine + Vincristine + Procarbazine + Prednisone
2 Radiotherapy + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2609 70A1 K-1: Stage IA, IIA; Unfavourable Sites; Entry OCT-1970 to MAR-1974; 58 patients were entered

1 Radiotherapy [subtotal nodal, 4400rad]
2 Radiotherapy [subtotal nodal, 4400rad] + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2610 70A2 R-1: Stage IA, IIA; Favourable sites; Entry AUG-1970 to FEB-1974; 20 patients were entered

1 Radiotherapy [mantle field or inverted Y, 4400rad]
2 Radiotherapy [involved field, 4400rad] + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2611 74A S-1: Stage IA, IIA; Age > 15; Entry APR-1974 to JUL-1980; 71 patients were entered

1 Radiotherapy (subtotal nodal)
2 Radiotherapy (involved field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2612 74F1 S-2: Stage IEA, IIEA; Age > 15; Entry 1974 to 1980; ? patients were entered (not received)

1 Radiotherapy (subtotal nodal) + (Mechlorethamine + Vinblastine + Procarbazine)
2 Radiotherapy (subtotal nodal) + Melphalan + Vinblastine + Procarbazine

2613 74F2 S-3: Stage IEB, IIEB; Age > 15; Entry 1974 to 1980; ? patients were entered (not received)

1 Radiotherapy (total nodal) + (Mechlorethamine + Vinblastine + Procarbazine)
2 Radiotherapy (total nodal) + Melphalan + Vinblastine + Procarbazine

2614 74F3 S-4: Stage IIA, IIIA; Age > 15; Entry 1974 to 1980; ? patients were entered (not received)

1 Radiotherapy (total nodal) + (Mechlorethamine + Vinblastine + Procarbazine)
2 Radiotherapy (total nodal) + Melphalan + Vinblastine + Procarbazine

2615 74F4 S-5: Stage IIB, IIIB; Age > 15; Entry 1974 to 1980; ? patients were entered (not received)

1 (Mechlorethamine + Vinblastine + Procarbazine) x 2 then Radiotherapy (total nodal) then (Mechlorethamine + Vinblastine + Procarbazine) x 4
2 (Melphalan + Vinblastine + Procarbazine) x 2 then Radiotherapy (total nodal) then (Melphalan + Vinblastine + Procarbazine) x 4

2616 80A1 C-1: Stage IA, IIA; Entry OCT-1980 to MAR-1988; 48 patients were entered

1 Radiotherapy (subtotal nodal)
2 Radiotherapy [involved field, 44Gy] + Vinblastine + M + Bleomycin

2617 80A2 C-2: Stage IB, IIB; Entry APR-1981 to DEC-1987; 10 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy [involved field, 44Gy] + Vinblastine + M + Bleomycin

2618 80A3 C-3: Stage IIIA; Entry SEP-1981 to DEC-1987; 14 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy [involved field, 44Gy] + Vinblastine + M + Bleomycin

2619 80C1 C-4: Stage IA, IIA; Bulky disease; Entry 1980 to 1987; ? patients were entered (not received)

1 Radiotherapy (extended field) + Melphalan + Procarbazine + Vinblastine
2 Radiotherapy (extended field) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

2620 80C2 C-5: Stage IB, IIB; Bulky disease; Entry 1980 to 1987; ? patients were entered (not received)

1 Radiotherapy (extended field) + Melphalan + Procarbazine + Vinblastine
2 Radiotherapy (extended field) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

2621 80C3 C-6: Stage IIIA; Bulky disease; Entry 1980 to 1987; ? patients were entered (not received)

1 Radiotherapy (total nodal) + Melphalan + Procarbazine + Vinblastine
2 Radiotherapy (total nodal) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

2622 80C4 C-7 / C-8 / C-9: Stage III; Entry 1980 to 1987; ? patients were entered (not received)

1 (Melphalan + Procarbazine + Vinblastine) + Radiotherapy (alternating)
2 (Melphalan + Procarbazine + Vinblastine) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) (alternating)

2623 80C5 C-10: Stage IV; Entry 1980 to 1987; ? patients were entered (not received)

1 (Melphalan + Procarbazine + Vinblastine) + Radiotherapy (alternating)
2 (Melphalan + Procarbazine + Vinblastine) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) (alternating)

2624 80C6 C-11: Relapsed disease; Entry 1980 to 1987; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Radiotherapy (involved field) then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2625 80C7 C-12: Stage IIIAs; Extensive splenic involvement; Entry 1984 ff; ? patients were entered (not received)

1 (Melphalan + Procarbazine + Vinblastine) x 6 + Radiotherapy (TLI) (alternating)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 6 (alternating)

2626 80C8 C-13: Stage IIIB; Entry 1984 ff; ? patients were entered (not received)

1 (Melphalan + Procarbazine + Vinblastine) x 6 + Radiotherapy (TLI) (alternating)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 6 (alternating)

2627 80C9 C-14: Stage IIIB; Entry 1984 ff; ? patients were entered (not received)

1 (Melphalan + Procarbazine + Vinblastine) x 6 + Radiotherapy (TLI) (alternating)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 6 (alternating)

2628 80C0 C-15: Stage IV; Entry 1984 ff; ? patients were entered (not received)

1 (Melphalan + Procarbazine + Vinblastine) x 6 + Radiotherapy (TLI) (alternating)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 6 (alternating)

2629 74J S-6: Stage IV; Age > 15; Entry MAY-1974 to FEB-1980; ? patients were entered (not received)

1 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisone) x 2 + Radiotherapy [mantle + inverted-Y] x 3 + (Nitrogen Mustard + Vincristine + Procarbazine + Prednisone) x 4
2 (Procarbazine + Melphalan + Vinblastine) x 2 + Radiotherapy [mantle + inverted-Y] x 3 + (Procarbazine + Melphalan + Vinblastine) x 4

2630 89A G-1: Stage Ia, IIa; Entry 1989 ff; 45 patients were entered by SEP-1991 (not received)

1 Radiotherapy [40-44Gy] (STLI,Spleen)
2 (Vinblastine + Bleomycin + Methotrexate) x 2 then Radiotherapy [30-36Gy] (mantle/minimantle) then (Vinblastine + Bleomycin [reduced dose] + Methotrexate) x 4

2631 88D Autologous Bone Marrow Transplant Patients: Relapsed Hodgkin's Disease or NHL; Entry 1988 to 1990; 27 patients were entered with Hodgkin's disease (not received)

1 GM-Colony Stimulating Factor [10µg/kg/d]
2 Control

27 Southwest Oncology Group, U.S.A. {Coltman, Dahlberg: AUG-1992 (UPDATED TWICE)}

2701 66B Chemotherapy Trial: Stage III, IV; Patients with other lymphomas were also entered; Entry 1966 to 1968; ? patients were entered (not received)

1 (Cyclophosphamide + Vincristine + Prednisone) then (Cyclophosphamide + Vincristine + Prednisone)
2 (Cyclophosphamide + Vincristine + Prednisone)

2702 68D SWOG-758: Stage III, IV; Entry 1968 to 1969; 197 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2703 69E SWOG-772: Stage III, IV; Entry 1969 to 1971; 130 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Actinomycin-D
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Methotrexate
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Vinblastine

2704 71F1 SWOG-774 / SWOG-775, induction: Stage IV; Entry 1971 to 1974; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin [2mg/m²]
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin [10mg/m²]

2705 71F2 SWOG-774 / SWOG-775, maintenance: Stage IV; Entry 1971 to 1974; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) (every other month for 18m)
2 Radiotherapy + (Mechlorethamine + Vincristine + Procarbazine + Prednisone) (every other month for 18m)

2706 72A SWOG-781: Stage I, II; Age 10-65; Entry JAN-1972 to AUG-1978; 281 patients were entered

1 Radiotherapy (total nodal)
2 Radiotherapy (involved field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2707 74G1 SWOG-7406 (3-Way): Stage IIIB, IV; Entry 1974 to 1975; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin + Doxorubicin
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin + Doxorubicin (different dose)

2708 75G SWOG-7518: Stage III; Entry 1975 to 1980; 137 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone + Bleomycin) x 10
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone + Bleomycin) x 3 + Radiotherapy (total nodal)

2709 78B SWOG-7808: Stage III, IV; Age > 15; Entry 1978 to 1987; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Doxorubicin + Bleomycin + Prednisone) then Radiotherapy (involved field)
2 Mechlorethamine + Vincristine + Procarbazine + Doxorubicin + Bleomycin + Prednisone + Bleomycin

2710 91A1 SWOG-????: Advanced Disease; Entry 1991 ff; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine)
2 (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

2711 91A2 SWOG-????: Earky-Stage Disease; Entry 1991 ff; ? patients were entered (not received)

1 Radiotherapy [40Gy, total nodal]
2 (Doxorubicin + Bleomycin + Vinblastine) x 3 + Radiotherapy [30-36Gy, mantle]

2712 74G2 SWOG-7406 (2-Way): Stage IIIB, IV; Entry 1975 to 1978; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Bleomycin + Doxorubicin

2713 Adriamycin Trial: Entry ?; 15 patients were entered (not received)

1 Doxorubicin [75mg/m²]
2 Doxorubicin [45mg/m²]

28 National Cancer Institute, Baltimore, U.S.A. {Dutcher, Longo, Wiernik: FEB-1993}

2801 65A Radiotherapy Trial: Stage I, II; Entry 1965 to 1969; 90 patients were entered (synthetic data only with no event; not received; data lost)

1 Radiotherapy (extended field)
2 Radiotherapy (total nodal)

2802 67C1 Chemotherapy/Radiotherapy Trial: Stage I, II; Entry 1967 to 1969; 22 patients were entered (data abstracted from publication)

1 Radiotherapy [extended field, 4000rad]
2 Radiotherapy [involved field, 4000rad] then (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 3
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 3 then Radiotherapy [involved field, 4000rad]

2803 67C2 Chemotherapy Trial: Stage III, IV; Entry 1967 to 1972; 57 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) then Bleomycin
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2804 70B CRP 7107: Stage IA, IIA, IIIA; Entry JUL-1970 to ?JUN-1975; 90 patients were entered (including 13 'exclusions' with synthetic data lacking dates; some other synthetic dates)

1 Radiotherapy (mantle field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (mantle field + periaortic nodes if mediastinal involvement)

2805 76E 7607: Stage IB, II, IIIA; Entry 1976 to 1978; ? patients were entered (not received)

1 Radiotherapy (extended field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2806 78A1 NCI-79-C-143 (3-Way): Stage I, II, IIIA; Entry 1978 to 1980; approx. 18 patients were entered (synthetic data, groups 1 and 3 only, no event; not received)

1 Radiotherapy
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
3 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy

2807 78A2 NCI-79-C-143 (2-Way): Stage I, II, IIIA (closed to IIIA in OCT-1983); Entry 1980 ff; ? patients were entered (not received)

1 Radiotherapy
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone)

2808 78D NCI-78-C-118: Stage III, IV; Entry 1978 to 1988; 133 patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6
2 ((Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 3 + (Streptozotocin + Lomustine + Doxorubicin + Bleomycin) x 3) (alternating)

2809 83D NCI-83-C-192: Patients who are likely to become neutropenic; Entry 1983 to 1987; ? patients were entered (not received)

1 Control
2 Prophylactic Gammaglobulin therapy

2810 CRP 7107: Stage IIIA; Entry JUL-1970 to DEC-1982; 28 patients were entered (now moved to 2804)

1 Radiotherapy (extended field) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (extended field)

29 European Organisation for Research on Treatment of Cancer {Henry-Amar: JUN-1992 (REVISED VERSION, UPDATED)}

2901 64A EORTC-H-1: Stage I, II; Entry 1964 to 1971; 296 patients were entered (not received)

1 Radiotherapy (regional)
2 Radiotherapy (regional) + Vinblastine

2902 72J1 EORTC-H-2, Splenectomy: Stage I, II; Entry 1972 to 1976; ? patients were entered (not received)

1 Radiotherapy (splenic)
2 Splenectomy

2903 72J2 EORTC-H-2, Chemotherapy: Stage I, II; Mixed cellularity or lymphocytic depletion; Entry 1972 to 1976; ? patients were entered (not received)

1 Vinblastine
2 Vinblastine + Procarbazine

2904 77C EORTC-H-5F: Stage I, II; Age 15-40 and no splenic involvement; Entry FEB-1977 to SEP-1982; 198 patients were entered

1 Radiotherapy (mantle field)
2 Radiotherapy (mantle field + para-aortic bar)

2905 77A1 EORTC-H-5U (Clinical Staging): Stage I, II; Age > 40 and/or splenic involvement; Entry JAN-1977 to AUG-1982; 257 patients were entered

1 Radiotherapy (total nodal)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy (mantle field)

2906 82D1 EORTC-H-6F: Stage I, II; Age 15-60; Favourable prognosis; Entry AUG-1982 to SEP-1988; 260 patients were entered

1 Staging laparatomy + Splenectomy + Radiotherapy (to neck, axillae, mediastinum)
2 Radiotherapy [to neck, axillae, mediastinum] + Radiotherapy [para-aortic, splenic, splenic hilus]

2907 82D2 EORTC-H-6U: Stage I, II; Age 15-60; Unfavourable prognosis; Entry 1982 to 1987; ? patients were entered (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy
2 (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) + Radiotherapy

2908 88B1 EORTC-20881 / EORTC-H7U: Stage I, II; Favourable; Age 15-70; Supradiaphragmatic disease; Entry 1988 ff; 211 patients were entered by SEP-1991 (not received)

1 Radiotherapy (subtotal nodal)
2 4-Epi-Doxorubicin + Bleomycin + Vinblastine + Prednisone + Radiotherapy (involved field)

2909 89B EORTC-H34: Stage III, IV; Entry 1989 ff; 175 patients were entered by AUG-1991 (not received)

1 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Doxorubicin + Bleomycin + Vinblastine + Radiotherapy (involved field)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Doxorubicin + Bleomycin + Vinblastine

2910 81C EORTC-H3B4: Stage IIIB, IV; Entry 1981 to 1986; 192 patients were entered (not received)

1 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 8
2 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 2 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 2 + (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 2 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 2

2911 88B2 EORTC-20881 / EORTC-H7U: Stage I, II; Unfavourable; Age 15-70; Supradiaphragmatic disease; Entry 1988 ff; 267 patients were entered by SEP-1991 (not received)

1 4-Epi-Doxorubicin + Bleomycin + Vinblastine + Prednisone + Radiotherapy (involved field)
2 Mechlorethamine + Vincristine + Procarbazine + Prednisone + Doxorubicin + Bleomycin + Vinblastine + Radiotherapy (involved field)

2912 77A2 EORTC-H-5U (Pathological Staging): Stage I, II; Age > 40 and/or splenic involvement; Entry FEB-1977 to JUN-1982; 39 patients were entered

1 Radiotherapy (total nodal)
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + Radiotherapy (mantle field)

30 Danish National Study Group, Denmark {Specht: SEP-1991}

3001 69C LYGRA-I: Stage I, II; Entry FEB-1969 to MAR-1971; 50 patients were entered

1 Radiotherapy (extended field)
2 Radiotherapy (involved field)

3002 71A LYGRA-II: Stage I, II; Entry AUG-1971 to MAY-1983; 327 patients were entered

1 Radiotherapy (mantle) + (Mechlorethamine + Vincristine + Procarbazine + Prednisone)
2 Radiotherapy (mantle + inverted field)

31 M.D. Anderson Hospital and Tumor Institute, Houston, U.S.A. {Fuller: JUL-1991}

3101 70E Part of RHDG Trial: Stage I, II; Entry 1970 to 1972; ? patients were entered (not received)

1 Radiotherapy (extended field)
2 Radiotherapy (involved field)

3102 81B MDA-DT-8071: Relapsed Disease; Entry 1981 to 1982; ? patients were entered (not received)

1 Ipp + Amsacrine + Etoposide
2 Ipp + Amsacrine + Teniposide

32 Northern Californian Oncology Group, U.S.A. {Hoppe: JUL-1991}

3201 86A NCOG-8H851: Stage I, II, IIIA; Age > 15; Entry 1986 ff; 100 patients were entered (synthetic data, no event; part of 2616-2618 except 2-4 non-Stanford patients; not received)

1 Radiotherapy (subtotal nodal)
2 Radiotherapy (involved field) + Vinblastine + Bleomycin + Methotrexate

3202 87C NCOG-8H852: Stage III, IV; Age > 15; Entry 1987 ff; ? patients were entered (not received)

1 Procarbazine + Melphalan + Vinblastine + Radiotherapy
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)

33 University La Sapienza, Rome, Italy {Mandelli: JUL-1991}

3301 79F Study-2: Stage I, IIA; Entry 1979 to 1982; 90 patients were entered (not received)

1 Radiotherapy (mantle field + lumbar bar)
2 Mechlorethamine + Vincristine + Procarbazine + Prednisone

3302 76F Study-3: Stage II (score > 4), III, IV; Entry 1976 to 1983; 218 patients were entered (not received)

1 (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 6
2 (Mechlorethamine + Vincristine + Procarbazine + Prednisone) x 6

34 Medical Research Council, U.K. {Lister: JUL-1991}

3401 70F Chemotherapy Trial: Stage IIIB, IV; Entry 1970 to 1975; 108 patients were entered (not received)

1 (Mechlorethamine + Vinblastine + Procarbazine + Prednisone) then Vinblastine + Procarbazine
2 (Mechlorethamine + Vinblastine + Procarbazine + Prednisone) then (Mechlorethamine + Vinblastine + Procarbazine + Prednisone)

3402 73B MRC-IIIA: Stage IIIA; Entry 1973 to 1978; 27 patients were entered (not received)

1 Radiotherapy (total nodal)
2 (Mechlorethamine + Vinblastine + Procarbazine + Prednisone)

35 Praha Facult Hospital, Czech Republic {Andrysek: JUL-1991}

3501 77H CHECO-1: Age 18-70; Patients in remission; Entry 1977 to 1979; ? patients were entered (not received)

1 BCG
2 Control

36 Cairo University, Egypt {Barsoum: JUL-1991}

3601 Radiotherapy Trial: Stage I, II, IIIA; Entry ????; 66 patients were entered (not received)

1 Radiotherapy (mantle field + inverted-Y)
2 Radiotherapy (lymph nodes)

37 Fondation Bergonié, Bordeaux, France {Hoerni: JUL-1991}

3701 69B Immunotherapy Trial: Stage I, II, III, IV; Bad prognosis; Patients in remission; Entry 1969 to 1973; 30 patients were entered (not received)

1 BCG
2 Control

38 French Society of Paediatric Oncology, France {Leverger: JUL-1991}

3801 82E Chemotherapy Trial: Stage IA, IIA; Entry 1982 ff; 128 patients were entered (not received)

1 (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 4 then Radiotherapy
2 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 2 + (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) x 2 then Radiotherapy

39 Groupe d'Études sur la Maladie de Hodgkin, France {Andrieu: JUN-1992 (UPDATED)}

3901 69D H-(9)-69: Stage I, II, III; Entry 1969 to 1972; ? patients were entered (not received)

1 Radiotherapy
2 Radiotherapy + Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone

3902 72K H-7202: Entry 1972 to 1975; ? patients were entered (not received)

1 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) then Laparatomy then Radiotherapy
2 Laparatomy then (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) then Radiotherapy

3903 77B H-7701: Stage IA, IIA; Entry JAN-1977 to APR-1980; 79 patients were entered

1 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 3 then Radiotherapy [mantle field, 40Gy]
2 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 3 then Radiotherapy [involved field, 40Gy]

3904 77K H-7702 / H-7703: Stage I, II, IIIA; Entry 1977 to 1980; ? patients were entered (not received)

1 Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone
2 Cyclophosphamide + Vinblastine + Procarbazine + Prednisone

40 Groupe Pierre et Marie Curie, Paris, France {Bonichon, Najman: AUG-1991}

4001 76A H-76.FB / UICC 77016: Stage I, II, IIIA; Entry JAN-1977 to MAR-1982; 335 patients were entered

1 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) then Radiotherapy (involved fields)
2 (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) then Radiotherapy (extended fields)

41 Hôpital Saint-Louis, Paris, France {Ferme: JUL-1991}

4101 Chemotherapy Trial: Stage I, II, III; Entry ????; ? patients were entered; {not properly randomised} (not received)

1 Radiotherapy (extended field) + (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 3
2 Radiotherapy (extended field) + (Nitrogen Mustard + Vincristine + Procarbazine + Prednisolone) x 6

42 Institut Gustave Roussy, Villejuif, France {Henry-Amar: JUL-1991}

4201 64B1 Chemotherapy Trial: Stage I, II; Entry 1964 ff; ? patients were entered (not received)

1 &n